Novel-Time-1279 t1_j7mdfcu wrote on February 7, 2023 at 9:07 PM

To what extend (if any) do you think that a database profiling common human genetic variation in eg KRAS tumors would be helpful so that you can design antibodies that will be broadly applicable? Do you analyze mass datasets from eg TCGA or Genomics England and try to design antibodies considering common variants or do you pick a canonical target and work from there?

IHaque_Recursion t1_j7mqu1g wrote on February 7, 2023 at 10:35 PM

I have genetics on the brain, so yes: I definitely think that data from both germline GWAS and somatic variation studies can be valuable for drug discovery. We don’t work on antibodies at Recursion today (though we have piloted them and they worked great on the platform), but we certainly make use of genetics data to inform our directions. As far as canonical targets, our platform allows us to be agnostic and to explore without having to select a target. As we move through our drug discovery process we aim to understand as much as possible about the target and its mechanism of action.